Leah Kuntz

Neuroimaging could help predict clinical response to treatment in bipolar depression.

New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.

Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.

In honor of Memorial Day...

Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.

Psychiatric Times’ very own H. Steven Moffic, MD, spoke about resilience and religion at the 2023 APA Annual Meeting.

Learn more about women’s issues, suicide, and PTSD in the military.

Deutetrabenazine extended-release tablets are now available.

Here are some things to check out in the city while you're in town...

Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

Ulotaront, a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity, is under investigation for the treatment of generalized anxiety disorder.

New results for a study evaluating lumateperone.

Recent research evaluated evenamide as an add-on to an antipsychotic for patients with treatment-resistant schizophrenia.

We connected with a group working on the frontlines of Southern Turkey and Northern Syria to assist the survivors of the devastating earthquake.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Transcranial direct current stimulation for depression.

What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?

A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

The FDA has accepted the NDA for nasal nalmefene, OPNT003, to treat opioid overdose.

Celebrating 25 years of Poetry of the Times with Richard Berlin, MD!

New approval for schizophrenia and bipolar I disorder.

How can you better provide care for American Indians and Alaska Natives?

The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.

VR-based training may help improve social cognition and functioning in patients with schizophrenia.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

What's the latest in dementia?

Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.

Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!